Immix Biopharma Stock On Fire: Up 70% With 6-Day Winning Streak
Immix Biopharma (IMMX) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 70% return. The company has gained about $27 Mil in value over the last 6 days, with its current market capitalization at about $67 Mil. The stock remains 205.9% above its value at the end of 2024. This compares with year-to-date returns of 17.1% for the S&P 500.
Immix Biopharma’s recent streak surged on impressive Phase 2 NXC-201 data, showing a 75% complete response rate in AL Amyloidosis patients and projecting 95%, significantly better than current therapies. This clinical breakthrough, coupled with a successful $100 million financing and an analyst target hike to $12, fuels optimism for a 2026 BLA submission.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.For quick background, IMMX provides development of tissue-specific oncology and inflammation therapeutics, including IMX-110 in clinical trials for soft tissue sarcoma and solid tumors, with collaboration on combination therapies.
Comparing IMMX Stock Returns With The S&P 500
The following table summarizes the return for IMMX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IMMX | S&P 500 |
|---|---|---|
| 1D | 2.0% | 0.7% |
| 6D (Current Streak) | 69.5% | 0.8% |
| 1M (21D) | 107.7% | 0.8% |
| 3M (63D) | 203.2% | 4.5% |
| YTD 2025 | 205.9% | 17.1% |
| 2024 | -68.2% | 23.3% |
| 2023 | 202.2% | 24.2% |
| 2022 | -35.7% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 61 S&P constituents with 3 days or more of consecutive gains and 45 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 18 | 22 |
| 4D | 13 | 10 |
| 5D | 2 | 2 |
| 6D | 12 | 4 |
| 7D or more | 16 | 7 |
| Total >=3 D | 61 | 45 |
Key Financials for Immix Biopharma (IMMX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-16.1 Mil | $-22.7 Mil |
| Net Income | $-15.4 Mil | $-21.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-6.7 Mil | $-7.7 Mil |
| Net Income | $-6.6 Mil | $-7.6 Mil |
While IMMX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.